Ecoool made a good point here
"I still fear the big risk is whoever the Prof is dealing with from a partnering point of view doing the numbers and realizing that this is a product capable of adding $US30 billion to their valuation right NOW (that's how much Gilead went up on Remdesivir and Moderna added a similar amount before falling back) - yet they can buy the whole thing for $US1.5 billion and get all the other P3 trials and products for free.That's ridiculously attractive for a big pharma, and the pressure point is now, before they sign a contract that would push the MSB price significantly higher and make a takeover much more expensive."
Something to think about
Ecoool made a good point here"I still fear the big risk is...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.020(1.87%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.11 | $1.07 | $4.338M | 3.980M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13222 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 61499 | 3 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.020 ( 1.42 %) |
||||
| Open | High | Low | Volume | ||
| $1.08 | $1.11 | $1.07 | 875231 | ||
| Last updated 15.59pm 13/06/2024 ? | |||||
| MSB (ASX) Chart |